PRAX stock forecast, quote, news & analysis
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company... Show more
Why Praxis Precision Medicines (PRAX) Stock Is Down 20% in the Last 30 Days
Key Takeaways
- PRAX fell roughly 20% over the last 30 days, sliding from $375.94 on August 21 to $298.95 at the September 18 close.
- The pullback followed a sharp rally triggered by second-quarter 2026 results, reflecting profit-taking after the stock touched an intraday peak above $390 in mid-August.
- The relutrigine regulatory decision was shifted from late September to December 27, 2026, removing a near-term catalyst from the calendar.
- Praxis ended the second quarter with approximately $1.4 billion in cash and investments and four late-stage product candidates.
- Key upcoming milestones include EMERALD study results in the fourth quarter and PDUFA dates for both relutrigine and ulixacaltamide.
Praxis Precision Medicines (PRAX) Company Overview and Market Position
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company translates genetic insights into therapies through two proprietary platforms: the Cerebrum™ small molecule platform and the Solidus™ antisense oligonucleotide (ASO) platform. Its pipeline spans movement disorders and epilepsy, anchored by four late-stage candidates — ulixacaltamide for essential tremor, relutrigine for SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs), vormatrigine for focal onset seizures and generalized epilepsy, and elsunersen, an ASO developed in collaboration with Ionis Pharmaceuticals (IONS) for early-seizure-onset SCN2A-DEE. Investors follow PRAX closely because the company is preparing to transition toward becoming a commercial-stage organization with two New Drug Applications already under FDA review.
Praxis Precision Medicines (PRAX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PRAX has declined approximately 20%, moving from a closing price of $375.94 on August 21 to $298.95 on September 18. The slide was steady rather than abrupt, with the stock giving back most of the gains it accumulated following its second-quarter earnings report in early August.
The longer view tells a more nuanced story. Over the trailing quarter, PRAX is essentially flat — down roughly 1.5% from a June 22 close of $303.39 — but the path has been volatile. The stock traded down to about $290 in late July, surged roughly 28% to an intraday high above $390 in mid-August, and has since retraced back toward the $299 level. In other words, the recent 30-day decline largely unwinds a sharp, catalyst-driven rally rather than breaking down to new multi-quarter lows.
What Drove PRAX Stock Price in the Last 30 Days
The 30-day decline appears driven primarily by profit-taking and a thinning near-term catalyst calendar. After second-quarter results on August 6 sent shares up roughly 16% in a single session — from $319.23 to $370.16 — the stock continued climbing to a closing high of $386.33 on August 12 and an intraday peak near $392 on August 19. From there, momentum faded.
A key factor was the timing of the relutrigine approval decision. Praxis disclosed in its second-quarter report that, following the submission of additional sensitivity analyses that the FDA deemed a major amendment, the PDUFA target action date for relutrigine was extended to December 27, 2026. This pushed a widely anticipated regulatory catalyst out of the September window and gave investors less near-term reason to hold elevated positions. The stock drifted lower through most of September, and the September 18 session closed down 3.7% on elevated volume, finishing at $298.95.
What Drove PRAX Stock Performance Over the Last Quarter
The quarter's volatility was shaped by a mix of positive regulatory progress and a mixed clinical readout. Second-quarter results were well received: Praxis reported a net loss of $2.87 per share, beating consensus estimates of roughly $3.60, and announced that mid-cycle meetings for both ulixacaltamide and relutrigine had been completed with no major safety or efficacy concerns identified and no advisory committee planned. The company also reported that FDA BIMO inspections had concluded without a Form 483, and that elsunersen had received Breakthrough Therapy Designation.
Offsetting these developments, Praxis disclosed in June that the POWER1 Phase 2/3 study of vormatrigine in focal onset seizures did not meet its primary endpoint, though it did meet a secondary endpoint. The company also announced a July 2026 collaboration with Remagine Labs to develop a transdermal patch of ulixacaltamide aimed at broadening its addressable patient population. With roughly $1.4 billion in cash and investments providing a runway into 2028, the balance sheet supported the advance before the September retracement.
Trending AI Robots
For traders tracking volatile names like PRAX, Tickeron's Trending AI Robots page offers a curated view of its AI-powered trading bots. Tickeron operates hundreds of AI trading bots that monitor thousands of tickers across the market, but only the top-performing and most relevant bots are featured in this section. These bots vary in strategy, timeframe, and performance metrics, giving traders a way to explore different automated approaches to the same security. The page is designed to help users identify which AI-driven strategies are currently standing out, making it a practical starting point for those interested in systematic trading tools.
PRAX Stock Forecast Drivers: What Investors Should Watch Next
Several milestones are likely to shape PRAX's trajectory in the months ahead. Top-line results from the EMERALD study of relutrigine in a broad DEE population — which enrolled approximately 200 patients across more than 50 genetic etiologies — are expected in the fourth quarter of 2026. The relutrigine PDUFA date of December 27, 2026, and the ulixacaltamide PDUFA date of January 29, 2027, represent the next major regulatory decision points. Investors will also monitor Praxis's plans to restart the POWER2 study and initiate POWER3 for vormatrigine, enrollment progress in the EMBRAVE3 registrational trial of elsunersen, and the company's ongoing commercial build-out ahead of potential product launches. As with all clinical-stage biotech companies, clinical outcomes, regulatory decisions, and cash management remain the primary risk factors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PRAX's RSI Oscillator stays in oversold zone for 9 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 260 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
PRAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRAX as a result. In 79 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for PRAX turned negative on August 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 39 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
PRAX moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PRAX crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for PRAX entered a downward trend on September 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.845) is normal, around the industry mean (26.424). P/E Ratio (0.000) is within average values for comparable stocks, (42.231). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.058). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology